Dr. Evan M. Landau, MD

Dr. Landau practices at Advocate Radiation Oncology in Port Charlotte, Florida.

Dr. Landau's NPI, 1184824088, was assigned on July 19, 2007. Dr. Landau graduated from Albert Einstein College of Medicine in 2006. Dr. Landau holds Florida license ME109336.

Dr. Landau's primary practice is Advocate Radiation Oncology, at 3080 Harbor Blvd, Port Charlotte, FL 33952 in Charlotte County. The practice phone is (941) 883-2199.

Dr. Landau's primary practice is Advocate Radiation Oncology in Port Charlotte, Florida. Dr. Landau is also affiliated with Broward Health Medical Center. The medical group on file is Advocate Radiation Oncology. Dmand AI also links Dr. Landau to 2 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Landau practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Landau's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Landau is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Landau's licenses on file in 2 states: Florida and New York.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, colorectal cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Landau treats.

CMS data shows 3,074 Medicare services from Dr. Landau across 19 procedure codes in 2024, for 185 Medicare patients. Medicare paid $504,465 for them.

CMS counts 185 Medicare patients who saw Dr. Landau in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Landau's median patient age at 71, with 47% women.

In 2024, Dr. Landau wrote 466 Medicare Part D claims for 149 patients. 86% of them were for generic drugs. CMS names the drug for 338 of them, across 10 drugs with 11 or more claims each, at $85,013 in total drug cost. In 2023, CMS named 209 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Landau for performance year 2024, reported as part of a group. Dr. Landau accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Landau, published from 2007 to 2024. Dr. Landau's most frequent co-authors are Shalom Kalnicki, MD, Steven E. Finkelstein, MD and Madhur K. Garg, MD.

Dmand AI links Dr. Landau to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 22 general payments to Dr. Landau from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Tactile Systems Technology Inc paid the most, $93.

Dmand AI lists 1 award for Dr. Landau, most recently CMS Stage 1 EHR in 2014.

Dr. Landau graduated from Albert Einstein College of Medicine in 2006.

Dr. Landau is in network with 16 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.